Expand HOTH Menu
HOTH MENU

HOTH Latest Press Releases

-- April 13, 2026 --

Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide PRNewswire 5:24 PM

-- April 2, 2026 --

Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering PRNewswire 4:05 PM

-- April 1, 2026 --

Hoth Therapeutics Announces $2.0 Million Registered Direct Offering PRNewswire 1:53 PM
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA =1 by Week Six PRNewswire 8:15 AM

-- March 31, 2026 --

Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology PRNewswire 8:07 AM

-- March 26, 2026 --

Hoth Therapeutics Deploys OpenClaw AI Platform to Accelerate Drug Discovery PRNewswire 8:30 AM

-- March 24, 2026 --

Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption PRNewswire 8:13 AM

-- March 10, 2026 --

Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model PRNewswire 8:13 AM

-- March 4, 2026 --

Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program PRNewswire 8:31 AM

-- February 24, 2026 --

HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES PRNewswire 4:15 PM

-- February 10, 2026 --

Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model PRNewswire 8:30 AM

-- February 5, 2026 --

Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets PRNewswire 8:03 AM

-- January 22, 2026 --

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients PRNewswire 8:13 AM

-- January 21, 2026 --

Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position PRNewswire 8:13 AM

-- January 15, 2026 --

Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation PRNewswire 8:17 AM

-- January 2, 2026 --

Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform PRNewswire 8:13 AM

-- December 3, 2025 --

Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program PRNewswire 2:00 PM

-- December 1, 2025 --

Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025 PRNewswire 8:03 AM

-- November 20, 2025 --

Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities PRNewswire 8:13 AM
Market Data Delayed 15 Minutes